14-03-2025
DocMorris Full Year 2024 Earnings: EPS Misses Expectations
Revenue: CHF1.03b (up 6.5% from FY 2023).
Net loss: CHF97.3m (loss narrowed by 17% from FY 2023).
CHF8.25 loss per share (improved from CHF10.07 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.0%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe.
Performance of the market in Switzerland.
The company's shares are down 26% from a week ago.
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with DocMorris (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
